CytomX Therapeutics, Inc. 8-K

What Happened
CytomX Therapeutics, Inc. announced and furnished a press release reporting its financial results for the year ended December 31, 2025. The press release, titled "CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update," was issued on March 16, 2026 and is furnished as Exhibit 99.1 to the Form 8-K (Item 2.02). The filing also includes the Exhibit reference under Item 9.01; the report was signed by CFO Christopher W. Ogden.

Key Details

• Filing date: March 16, 2026 (Form 8-K).
• Period covered: financial results for the year ended December 31, 2025.
• Exhibit: 99.1 — press release titled "CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update."
• Form 8-K items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).

Why It Matters
This 8-K notifies investors that CytomX has publicly released its full-year 2025 financial results and a business update. The press release will contain revenue, earnings (or loss), cash position, and any operational highlights or guidance that could affect the company’s valuation or near-term expectations. Retail investors should read the furnished press release (Exhibit 99.1) and the company’s subsequent SEC filings (such as the annual 10-K) for complete financial details and context before making investment decisions.